Curcumin-Based Photodynamic Therapy in Epidermolysis Bullosa: Wound Healing, Quality of Life, and Salivary Biomarkers (CURE-EB)

Impact of Photodynamic Therapy With Curcumin on Tissue Repair and Quality of Life in Patients With Epidermolysis Bullosa, and Identification of Salivary Biomarkers

Epidermolysis bullosa (EB) is a rare condition that causes extreme fragility of the skin and mucous membranes, leading to the formation of painful blisters. It can be hereditary (HEB) or autoimmune (AEB), and its diagnosis requires invasive procedures such as biopsies. Saliva emerges as a promising alternative for diagnosis and monitoring, as it is easy to collect and contains relevant biomarkers. The disease has no cure, and care focuses on improving the daily lives of those affected. Lesions in oral soft tissues are common and affect functions such as chewing and speech. Photodynamic therapy (PDT), especially with curcumin, has shown positive results in treating oral lesions in other conditions due to its antimicrobial and anti-inflammatory properties. However, it has not yet been specifically studied in people with EB. The primary objective of this study is to evaluate the efficacy of PDT with curcumin in repairing oral lesions in people with EB. Secondary objectives are to assess the impact of photodynamic therapy on the quality of life of people with EB and to identify potential salivary biomarkers and their correlation with the current gold-standard markers of EB. Participant selection and research will be carried out at the Reference Center for Neurodevelopment, Care and Rehabilitation of Children (NINAR), in São Luís, Maranhão, in July 2025. Children, adolescents and adults diagnosed with EB who feed orally, as well as people without EB, will be included in the study. A single calibrated evaluator will be responsible for administering the questionnaires, performing the clinical examination, collecting saliva, and carrying out PDT. Demographic and socioeconomic information will be collected from participants and guardians. Dietary intake will be assessed using a 77-item food frequency questionnaire (FFQ) validated by ELSA-BRASIL (Chor et al., 2013). The following clinical data will be collected: dental caries, using the ICDAS system [scores 0 (healthy tooth), 5 (visible dentinal cavity) and 6 (extensive cavity)] (Ismail et al., 2007); molar-incisor hypomineralization (MIH), using the SES-MIH index (Cabral et al., 2019); soft tissue lesions (ulcers, vesicles, bullae), coloration (whitish, yellowish, reddish, etc.) and location (lips, tongue, palate, buccal mucosa, gingiva, etc.). Unstimulated saliva will be collected from EB participants at the NINAR facility and from non-EB participants (control) at the Ana Lúcia Chaves Fecury Clinical School. Saliva samples will be obtained using a 1 mL syringe between 7:00 and 10:00 AM, stored in Eppendorf tubes under refrigeration and subsequently in an ultrafreeze unit (-80°C) at the University of Ceuma. PDT will be performed with 0.1% curcumin gel, applied to the oral mucosal lesions for 5 minutes, followed by irradiation with a blue LED (Radii-CAL CX, 440/480 nm) for one and a half minutes. The procedure will be repeated for three consecutive days. Pain intensity will be monitored before and for seven days after treatment using the Wong-Baker FACES Scale (0 to 5). To assess the impact of treatment on the quality of life of children, the short-form Parental-Caregiver Perceptions Questionnaire (P-CPQ) will be completed by their parents or guardians. For adolescents (aged 12 and above) and adults, the Oral Health Impact Profile-14 (OHIP-14) will be applied. Both questionnaires will be administered before the 1st, 2nd, and 3rd PDT sessions. The reparative efficacy of PDT on lesions will be measured through clinical evaluation. Biochemical analyses will be performed at the laboratories of the Federal University of Uberlândia (UFU), including: metabolite extraction, mass spectrometry (ESI-MS and HPLC-MS), spectroscopy (ATR-FTIR), chemometric analysis, and identification of salivary biomarkers with the aid of artificial intelligence algorithms. Data will be subjected to descriptive analysis of qualitative variables (absolute and relative frequency) and quantitative variables (mean, standard deviation, median, and interquartile range). Statistical tests will be applied for intragroup comparison regarding treatment reparative efficacy and quality of life impact (before and after treatment days) and between groups (with and without EB) regarding salivary biomarkers. Statistical analyses will be conducted at a 5% significance level. SPSS for Windows (Version 20.0; SPSS Inc., Chicago) will be used for data analysis.

Study Overview

• Status: Active, not recruiting
• Conditions: Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa (EB); Epidermolysis Bullosa Acquisita
• Intervention / Treatment: Drug: Curcumin-based photodynamic therapy

Detailed Description

This study is a clinical investigation designed to evaluate the efficacy of curcumin-mediated photodynamic therapy (PDT) on tissue repair of oral vesiculobullous lesions in patients with epidermolysis bullosa (EB), as well as its impact on quality of life and the identification of salivary biomarkers associated with disease status and healing processes. EB is a rare disorder characterized by extreme fragility of the skin and mucosa, leading to painful blister formation and chronic lesions that significantly impair oral function, nutrition, and overall quality of life. Given the absence of curative treatments, therapeutic strategies that promote tissue repair and reduce symptom burden are of high clinical relevance.

Participants will include children, adolescents, and adults diagnosed with EB who are able to feed orally, as well as a control group without EB matched by age and sex. Recruitment will take place at a specialized reference center for neurodevelopment and rehabilitation, with additional control sampling conducted at a university-based clinical facility. All participants or their legal guardians will provide informed consent prior to enrollment, and assent will be obtained from minors when applicable.

The study protocol includes clinical evaluation, questionnaire-based assessments, salivary sample collection, and application of photodynamic therapy. Clinical oral examination will assess dental caries using the International Caries Detection and Assessment System (ICDAS), molar-incisor hypomineralization using the SES-HMI index, and soft tissue lesions characterized by type, color, and anatomical location. Pain intensity associated with oral lesions will be measured using the Wong-Baker Faces Pain Rating Scale at baseline and for seven consecutive days following treatment.

Photodynamic therapy will be performed using a 0.1% curcumin gel applied topically to oral lesions for five minutes, followed by irradiation with a blue LED light source (wavelength 440-480 nm) for approximately 90 seconds, delivering an estimated energy dose of 9 J. The procedure will be repeated over three consecutive days. The primary outcome is tissue repair, assessed clinically, while secondary outcomes include pain reduction and improvement in oral health-related quality of life.

Quality of life will be evaluated using validated instruments appropriate to age group. For children, the Parental-Caregiver Perceptions Questionnaire (P-CPQ) will be administered to caregivers, while adolescents and adults will complete the Oral Health Impact Profile (OHIP-14). These instruments will be applied prior to each PDT session to assess changes over time. Dietary intake will also be assessed using a validated food frequency questionnaire to account for potential nutritional influences on oral health and healing.

Saliva will be collected as a non-invasive biological fluid for biomarker discovery. Unstimulated saliva samples will be obtained in the morning using standardized procedures, stored under controlled conditions, and analyzed using advanced omics approaches, including mass spectrometry (ESI-MS and LC-MS), Fourier-transform infrared spectroscopy (ATR-FTIR), and chemometric analysis. Data processing will include normalization, spectral correction, and multivariate analysis such as principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA). Machine learning algorithms-including logistic regression, linear discriminant analysis, random forest, and support vector machines-will be applied to classify and identify relevant biomarker patterns. Model validation will be conducted using repeated stratified cross-validation procedures.

Quality assurance procedures will be implemented to ensure data integrity and protocol adherence. A standardized data collection framework will be used, with all study personnel trained and calibrated prior to data acquisition. Data entry will follow predefined validation rules, including range checks, logical consistency checks, and automated verification procedures to identify discrepancies or missing values. Source data verification will be conducted through comparison with original clinical records and case report forms to ensure accuracy and completeness.

A comprehensive data dictionary will be developed, defining all variables collected in the study, including their sources, coding structures, permissible values, and reference ranges where applicable. Standardized terminologies and classifications will be applied when relevant to ensure interoperability and reproducibility. Standard Operating Procedures (SOPs) will guide all stages of the study, including participant recruitment, clinical examination, sample collection and handling, data management, statistical analysis, adverse event reporting, and protocol deviations.

Monitoring procedures will include periodic internal review of study conduct, adherence to protocol, and data quality. Although this is a single-center study, audit readiness will be ensured through proper documentation and traceability of all procedures. Any protocol amendments or deviations will be documented and managed وفق established change control processes.

The sample size is defined based on the available population of EB patients treated at the recruitment center, given the rarity of the condition. While formal power calculation is limited by feasibility constraints, the study is designed to generate exploratory and hypothesis-generating data regarding treatment efficacy and biomarker identification.

Missing data will be handled using predefined strategies depending on the nature and extent of missingness. Data will be categorized as missing, not applicable, or not interpretable, and appropriate statistical techniques such as imputation or sensitivity analyses will be considered where necessary to minimize bias.

Statistical analysis will include descriptive statistics for all variables, with qualitative data expressed as frequencies and percentages and quantitative data summarized using means, standard deviations, medians, and interquartile ranges. Inferential analyses will be conducted to compare outcomes within groups (pre- and post-treatment) and between groups (EB versus controls). Parametric or non-parametric tests will be applied בהתאם data distribution, with a significance level set at 5%. Receiver Operating Characteristic (ROC) curve analysis will be used to evaluate the diagnostic performance of identified biomarkers, and correlation analyses will assess associations between clinical findings and molecular data.

All analyses will be performed using validated statistical software. The study follows recognized clinical research guidelines and ethical standards, ensuring participant safety, confidentiality, and scientific rigor. The results are expected to contribute to the development of innovative, non-invasive therapeutic and diagnostic strategies for patients with epidermolysis bullosa.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 4

Contacts and Locations

Study Locations

• Brazil
  • Maranhão
    • São Luís, Maranhão, Brazil, 65075340
      • Rua Perdizes, Quadra 35, n. 27/805, Jardim Renascença

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Children, adolescents, and adults diagnosed with epidermolysis bullosa (EB), regardless of subtype
• Participants who are able to receive oral feeding Individuals receiving care at the NINAR Reference Center or residing in São Luís or the state of Maranhão
• Participants (or legal guardians) who provide written informed consent; assent obtained from minors when applicable
• Ability to undergo oral clinical examination and photodynamic therapy procedures

Exclusion Criteria:

• Individuals with epidermolysis bullosa who present physical and/or mental conditions that prevent cooperation with oral examination or treatment procedures
• Participants unable to comply with study procedures, including clinical evaluation, saliva collection, or photodynamic therapy
• Individuals with conditions that contraindicate the application of photodynamic therapy in the oral cavity (e.g., severe intolerance to light exposure or topical agents)
• Participants currently undergoing other experimental treatments that may interfere with the study outcomes

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Curcumin Photodynamic Therapy in EB Patients; Participants diagnosed with epidermolysis bullosa (EB) will receive curcumin-mediated photodynamic therapy (PDT) for the treatment of oral vesiculobullous lesions. The intervention consists of topical application of 0.1% curcumin gel directly onto oral lesions, maintained for 5 minutes, followed by irradiation with a blue LED light source (wavelength 440-480 nm) for approximately 90 seconds (≈9 J). The procedure will be performed once daily for three consecutive days. Clinical evaluation of lesions, pain assessment using the Wong-Baker Faces Pain Scale, and quality of life questionnaires (P-CPQ or OHIP-14) will be conducted before and after treatment. Saliva samples will also be collected for biomarker analysis.

Drug: Curcumin-based photodynamic therapy; Curcumin-mediated photodynamic therapy (PDT) will be applied to oral vesiculobullous lesions in patients with epidermolysis bullosa. A 0.1% curcumin gel will be topically administered directly onto the lesion and maintained for 5 minutes to allow adequate tissue absorption. Following this, the area will be irradiated using a blue LED light source with a wavelength of 440-480 nm for approximately 90 seconds, delivering an estimated energy dose of 9 J using a scanning technique. The procedure will be performed once daily for three consecutive days. This protocol is standardized and performed by a single calibrated examiner to ensure consistency. The intervention is non-invasive and aims to promote tissue repair, reduce microbial load, and alleviate pain associated with oral lesions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tissue Repair of Oral Vesiculobullous Lesions	The primary outcome is the clinical evaluation of tissue repair in oral vesiculobullous lesions following curcumin-mediated photodynamic therapy. Lesions will be assessed through standardized oral examination considering presence, type (ulcer, vesicle, or blister), color, and anatomical location. Changes in lesion characteristics and healing progression will be evaluated by a single calibrated examiner. Improvement will be defined by reduction or resolution of lesions and overall clinical appearance of mucosal healing after treatment.	Baseline (pre-treatment) and daily assessment for 7 days after completion of the 3-day treatment protocol.

Collaborators and Investigators

• Sponsor: Universidade Ceuma

Publications and helpful links

General Publications

• Rocha BA, Melo Filho MR, Simoes A. Antimicrobial Photodynamic Therapy to treat chemotherapy-induced oral lesions: Report of three cases. Photodiagnosis Photodyn Ther. 2016 Mar;13:350-352. doi: 10.1016/j.pdpdt.2015.07.172. Epub 2015 Jul 26.

Study record dates

Study Major Dates

• Study Start (Actual): January 12, 2026
• Primary Completion (Actual): January 23, 2026
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: May 12, 2026
• First Submitted That Met QC Criteria: May 12, 2026
• First Posted (Actual): May 19, 2026

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Photodynamic Therapy; Epidermolysis Bullosa; Salivary Biomarkers
• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Connective Tissue Diseases; Skin Diseases; Congenital Abnormalities; Skin Diseases, Genetic; Skin Abnormalities; Skin Diseases, Vesiculobullous; Collagen Diseases; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin and Connective Tissue Diseases; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa Acquisita
• Other Study ID Numbers: CURE-EB-PTD-2026-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No